vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and FIVE STAR BANCORP (FSBC). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $45.1M, roughly 1.7× FIVE STAR BANCORP). FIVE STAR BANCORP runs the higher net margin — 41.3% vs -9.6%, a 50.9% gap on every dollar of revenue. Over the past eight quarters, FIVE STAR BANCORP's revenue compounded faster (21.3% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

BIOX vs FSBC — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.7× larger
BIOX
$77.6M
$45.1M
FSBC
Higher net margin
FSBC
FSBC
50.9% more per $
FSBC
41.3%
-9.6%
BIOX
Faster 2-yr revenue CAGR
FSBC
FSBC
Annualised
FSBC
21.3%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
FSBC
FSBC
Revenue
$77.6M
$45.1M
Net Profit
$-7.4M
$18.6M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
-9.6%
41.3%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
42.0%
EPS (diluted)
$-0.12
$0.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
FSBC
FSBC
Q1 26
$45.1M
Q4 25
$43.5M
Q3 25
$77.6M
$41.3M
Q2 25
$38.3M
Q1 25
$60.6M
$35.3M
Q4 24
$98.8M
$35.2M
Q3 24
$93.3M
$31.8M
Q2 24
$30.7M
Net Profit
BIOX
BIOX
FSBC
FSBC
Q1 26
$18.6M
Q4 25
$17.6M
Q3 25
$-7.4M
$16.3M
Q2 25
$14.5M
Q1 25
$-1.6M
$13.1M
Q4 24
$605.2K
$13.3M
Q3 24
$-6.2M
$10.9M
Q2 24
$10.8M
Gross Margin
BIOX
BIOX
FSBC
FSBC
Q1 26
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Operating Margin
BIOX
BIOX
FSBC
FSBC
Q1 26
Q4 25
52.9%
Q3 25
9.3%
53.8%
Q2 25
52.4%
Q1 25
1.5%
52.0%
Q4 24
14.5%
55.1%
Q3 24
2.5%
48.0%
Q2 24
49.4%
Net Margin
BIOX
BIOX
FSBC
FSBC
Q1 26
41.3%
Q4 25
40.6%
Q3 25
-9.6%
39.6%
Q2 25
37.9%
Q1 25
-2.6%
37.1%
Q4 24
0.6%
37.9%
Q3 24
-6.6%
34.4%
Q2 24
35.2%
EPS (diluted)
BIOX
BIOX
FSBC
FSBC
Q1 26
$0.87
Q4 25
$0.83
Q3 25
$-0.12
$0.77
Q2 25
$0.68
Q1 25
$-0.02
$0.62
Q4 24
$0.00
$0.61
Q3 24
$-0.10
$0.52
Q2 24
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
FSBC
FSBC
Cash + ST InvestmentsLiquidity on hand
$15.5M
$644.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$458.5M
Total Assets
$734.9M
$5.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
FSBC
FSBC
Q1 26
$644.4M
Q4 25
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
Stockholders' Equity
BIOX
BIOX
FSBC
FSBC
Q1 26
$458.5M
Q4 25
$445.8M
Q3 25
$288.3M
$431.3M
Q2 25
$416.7M
Q1 25
$345.0M
$406.5M
Q4 24
$346.3M
$396.6M
Q3 24
$346.0M
$389.9M
Q2 24
$380.5M
Total Assets
BIOX
BIOX
FSBC
FSBC
Q1 26
$5.0B
Q4 25
$4.8B
Q3 25
$734.9M
$4.6B
Q2 25
$4.4B
Q1 25
$798.2M
$4.2B
Q4 24
$835.2M
$4.1B
Q3 24
$827.3M
$3.9B
Q2 24
$3.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
FSBC
FSBC
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
FSBC
FSBC
Q1 26
Q4 25
$72.6M
Q3 25
$14.4M
$18.8M
Q2 25
$17.8M
Q1 25
$23.3M
$15.5M
Q4 24
$-5.4M
$51.8M
Q3 24
$5.2M
$17.5M
Q2 24
$16.0M
Free Cash Flow
BIOX
BIOX
FSBC
FSBC
Q1 26
Q4 25
$71.4M
Q3 25
$18.6M
Q2 25
$17.5M
Q1 25
$15.4M
Q4 24
$51.2M
Q3 24
$17.3M
Q2 24
$15.8M
FCF Margin
BIOX
BIOX
FSBC
FSBC
Q1 26
Q4 25
164.3%
Q3 25
45.0%
Q2 25
45.8%
Q1 25
43.5%
Q4 24
145.5%
Q3 24
54.5%
Q2 24
51.6%
Capex Intensity
BIOX
BIOX
FSBC
FSBC
Q1 26
Q4 25
2.8%
Q3 25
0.5%
Q2 25
0.6%
Q1 25
0.3%
Q4 24
1.8%
Q3 24
0.7%
Q2 24
0.7%
Cash Conversion
BIOX
BIOX
FSBC
FSBC
Q1 26
Q4 25
4.12×
Q3 25
1.15×
Q2 25
1.23×
Q1 25
1.18×
Q4 24
-8.85×
3.89×
Q3 24
1.60×
Q2 24
1.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

FSBC
FSBC

Net Interest Income$43.5M96%
Noninterest Income$1.6M4%

Related Comparisons